​  > Main Congress










It’s very rare to get an opportunity to be interacting with other researchers who are interested in a completely different research area, compared to the same people you always meet when you go to an immunotherapy/oncology conference. It’s really a great opportunity to get the latest and greatest about the science, but also to interact with colleagues that normally you wouldn’t have a chance to meet with.                 








Prof Ramy Ibrahim  
Vice President, Clinical Development, Parker Institute for Cancer Immunotherapy


Programme >

Radiological Sciences and Surgery Symposium
Targeted Therapy and Personalised Medicine of Hepatocellular Carcinomas

 Track type: Symposium

Date: 18 Sep 2021


 Time: 0935 - 1105

Location: Seminar Room 6

Hepatocellular Carcinoma (HCC) is a complex disease and it is widely accepted that a multidisciplinary team approach is the best to tailor a personalised management. This generally depends on multiple factors such as tumour burden, extent of hepatic dysfunction, morbid medical conditions and patient preference. Treatment options range from curative surgery for resectable disease, to locoregional therapy such as radiofrequency ablation, or palliative options which include chemotherapy, immunotherapy, transarterial chemoembolisation and Y90 hepatic radioembolisation.

Subspeciality experts from surgery, medical oncology, interventional radiology and nuclear medicine will provide  updates on the treatment options and highlight research findings from phase 3 clinical trials such as Checkmate 040, SIRveNIB (AHCC 06) and ongoing PLANet AHCC07 trials. The speakers from oncologic imaging radiology will also share their experiences in employing artificial intelligence to identify radiomics signature of HCC.


Downstaging Locally Advanced HCC to Curative Resection

SpeakerProf Pierce Chow 



Awakening the Immune System Against Liver Cancer: The Time is Now


Speaker: Assoc Prof Toh Han Chong



Next Frontier of Liver Imaging?


SpeakerDr Chan Wan Ying



Radionuclide Therapy for Hepatocellular Carcinomas – Nuclear Theranostics and Personalised Patient Dosimetry


SpeakerDr Aaron Tong Kian Ti



Percutaneous and Endovascular Treatments for Hepatocellular Carcinoma

*Information is correct at time of update